Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kai M Beeh

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Pulmonary Therapy|February 7, 2020
And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?Kai M Beeh
Advances in Therapy|November 27, 2013
"All I want for christmas is two": the advent of novel fixed-combination inhalers for COPD and outlook for 2014Kai M Beeh
Tuberculosis and Respiratory Diseases|October 30, 2016
The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseaseKai M Beeh
Advances in Therapy|April 23, 2010
The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary diseaseKai M Beeh, Jutta Beier
Advances in Therapy|July 18, 2009
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseasesKai M Beeh, Jutta Beier
International Journal of Chronic Obstructive Pulmonary Disease|August 5, 2011
Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterolJutta Beier, Kai M Beeh
Core Evidence|August 10, 2010
Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonistKai M Beeh, Jutta Beier
COPD|October 30, 2009
Is there a role for antiinflammatory treatment in COPD?Kai M Beeh, Thomas Glaab
Pulmonary Pharmacology & Therapeutics|March 3, 2015
Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPDMario Cazzola, Kai M Beeh, David Price, et al.
Expert Review of Medical Devices|August 18, 2025
Comment on 'comparative validation of handheld fractional exhaled nitric oxide measurements'Florian Mirschinka, Thomas Keller, Sandra Wegner, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Pulmonary Therapy|February 7, 2020
And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?Kai M Beeh
Advances in Therapy|November 27, 2013
"All I want for christmas is two": the advent of novel fixed-combination inhalers for COPD and outlook for 2014Kai M Beeh
Tuberculosis and Respiratory Diseases|October 30, 2016
The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseaseKai M Beeh
Advances in Therapy|April 23, 2010
The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary diseaseKai M Beeh, Jutta Beier
Advances in Therapy|July 18, 2009
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseasesKai M Beeh, Jutta Beier
International Journal of Chronic Obstructive Pulmonary Disease|August 5, 2011
Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterolJutta Beier, Kai M Beeh
Core Evidence|August 10, 2010
Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonistKai M Beeh, Jutta Beier
COPD|October 30, 2009
Is there a role for antiinflammatory treatment in COPD?Kai M Beeh, Thomas Glaab
Pulmonary Pharmacology & Therapeutics|March 3, 2015
Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPDMario Cazzola, Kai M Beeh, David Price, et al.
Expert Review of Medical Devices|August 18, 2025
Comment on 'comparative validation of handheld fractional exhaled nitric oxide measurements'Florian Mirschinka, Thomas Keller, Sandra Wegner, et al.
Pageof 4